0738 ET - The FDA approval of Vykat XR is a significant win for Soleno Therapeutics, say analysts at Stifel, who cite a very favorable and clean label and pricing that came in well above expectations. Stifel reiterates its buy rating on Soleno shares and says it thinks the drug is well positioned to launch strongly into a blockbuster opportunity, given a significant unmet need, a well-diagnosed/concentrated patient population, a favorable risk/benefit and high physician/patient awareness. Stifel, with a $74 target price on Soleno shares, says M&A remains a plausible upside case as well. Soleno surges 37% premarket to $67.22. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 27, 2025 07:38 ET (11:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。